Keating Capital is Lead Investor in Metabolon's Series D Financing

Metabolon Receives Growth Capital from Pre-IPO Investor

GREENWOOD VILLAGE, Colo., Aug 30, 2011 (BUSINESS WIRE) -- Keating Capital, Inc. ( www.KeatingCapital.com ), a pre-IPO investment fund, announced that on August 25, 2011, it made a $4 million investment in the $13 million Series D Convertible Preferred Stock round of Metabolon, Inc. ( www.Metabolon.com ) ("Metabolon"). Other investors in the Series D round include existing investors Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners.

Founded in 2000 and headquartered in Research Triangle Park, North Carolina, Metabolon is a molecular diagnostics and services company offering a novel metabolic profiling technology that uses advanced bioinformatics and data analytics software to identify, quantify, and analyze biochemical processes occurring within cells. Metabolon's end-to-end profiling service is used by leading academic institutions and pharmaceutical, biotechnology, agriculture, and consumer products companies to develop more efficacious drugs, diagnostic tests, and consumer and agricultural products. Metabolon is utilizing biomarkers identified by its technology in the development of molecular diagnostic tests intended to detect and measure the aggression and stage of diseases such as diabetes and cancer.

Timothy J. Keating, Keating Capital's CEO stated: "We are pleased to diversify our portfolio with the addition of our first life sciences company. We are delighted to be an equity partner with Metabolon, and we believe that the confluence of the company's outstanding management team, world class scientific advisory board and blue chip client roster will ultimately lead to major disruptive innovations in the delivery of medicines to patients worldwide."

Metabolon is Keating Capital's sixth new portfolio company investment in 2011. With this investment, Keating Capital has now invested a total of $23.0 million in 10 portfolio companies, of which $19.4 million has been invested in 2011."

To be added to Keating Capital's distribution list, go to www.KeatingCapital.com/contact .

About Keating Capital, Inc.

Keating Capital ( www.KeatingCapital.com ) is a business development company that specializes in making pre-IPO investments in innovative, high growth private companies that are committed to and capable of becoming public. Keating Capital provides individual investors with the ability to participate in a unique fund that invests in a private company's late stage, pre-IPO financing round -- an opportunity that has historically been reserved for institutional investors.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.